News and Information

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

Dendreon has reached agreements with certain of its senior noteholders on the terms of a financial restructuring. Operations will continue in the ordinary course and PROVENGE will remain available. Additional information about the financial restructuring is available here: https://cases.primeclerk.com/dendreon.

View all »   RSSRecent Releases

Nov 10, 2014
Dendreon Reaches Agreements on Terms of Financial Restructuring

Jul 30, 2014
Dendreon Names W. Thomas Amick President and Chief Executive Officer

Jun 9, 2014
Dendreon Announces Leadership Transition


Presentations and Information

Stipulation of Settlement of Certain Shareholder Litigation PDF 3.9 MB
MEDCAC 11.17.10 Presentation PDF 397.5 KB
Updated Results of the IMPACT Trial of Sipuleucel-T for Metastatic, Castration-Resistant Prostate Cancer (CRPC) PDF 421.1 KB

Contact

Media
206-829-1622
media@dendreon.com